Actively Recruiting
Randomized Double-Blind Study of Remibrutinib vs Placebo in Adults with Moderate to Severe Hidradenitis Suppurativa Evaluating Tissue-Level Effects
Led by Novartis Pharmaceuticals · Updated on 2026-10-16
30
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how remibrutinib, a Brutons tyrosine kinase BTK inhibitor, affects adults with moderate to severe hidradenitis suppurativa HS, a complex inflammatory skin condition characterized by different lesion types. This Phase 1, randomized, double-blind, placebo-controlled study aims to better understand the drugs mechanism of action at the tissue level. Participants will be randomly assigned to receive either remibrutinib or a matching placebo for 16 weeks during the treatment period. The total study duration is 24 weeks, including up to 4 weeks of screening, followed by the 16-week double-blind treatment phase, and a 4-week treatment-free follow-up period. Throughout the study, participants will undergo assessments to measure changes in auto-antibodies from baseline to Week 16, as well as monitoring for adverse events up to Week 20. The study includes physical exams, laboratory tests, and safety evaluations to track effects and ensure participant well-being during and after treatment.
CONDITIONS
Brief Title
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here